F10 and atrial fibrillation: The use of DOACs in this setting of patients is based on subgroup analyses of Randomized Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY) for dabigatran [16], from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial (ROCKET AF) for rivaroxaban [17], and from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial (ARISTOTLE) for apixaban [18].